Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development from 4 April 2019. Keld will be part of Executive Management in his role as Executive Vice President, CBO.

The new position is established as part of the revised strategy which focuses on achievement of sustainable growth. This focus demands that Lundbeck supplements its internally generated pipeline with high quality assets from external sources. We will access this external innovation through product license and/or acquisitions as well as through strategic partnerships.

Keld will join the company from a position as Global Head of Strategic Partnering for Roche. Since 2011 Keld has worked in business development and partnering across multiple therapy areas, including CNS. During this period, he has been leading multiple global M&A projects, pharma and biotech partnering initiatives and strategic projects, building creative partnerships and deals to expand the Roche pipeline. Keld was born in Denmark and holds a BSc in Economics and Business Administration and a MSc in Business Economics and Auditing from Copenhagen Business School.

“I am looking forward to having Keld join the Lundbeck team, adding his expertise to our Expand and Invest for Growth strategy,” says Deborah Dunsire; President and CEO of Lundbeck. “Creating this additional executive role allows for sufficient management resources devoted to ensuring that we can continue growing our commercial presence and deliver on our growth strategy including access to appropriate external innovation.”

“I am very pleased to be joining Lundbeck and look forward to be driving the development and execution of the corporate strategy going forward. In addition to the company’s core business, the intention is to devote significant time and effort to pursuing external opportunities which offers significant opportunities for value creation” says Keld Jørgensen.

Following today’s announcement, the executive management of Lundbeck is comprised of:

• Deborah Dunsire, President & CEO
• Peter Anastasiou, EVP, North America
• Lars Bang, EVP, Product Development & Supply
• Anders Götzsche, EVP & CFO
• Keld Flintholm Jørgensen, EVP & CBO (as of 4 April 2019)
• Johan Luthman, EVP, R&D
• Jacob Tolstrup, EVP, Commercial Operations

Lundbeck contacts
Investors:                                                                                 Media:
Palle Holm Olesen                                                                   Mads Kronborg
Vice President, Investor Relations                                           Senior Director, Corp. Communication
PALO@lundbeck.com                                                             MAVK@lundbeck.com         
+45 30 83 24 26                                                                      +45 36 43 40 00

About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind. 

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Attachment

• EVP_CBO_UK_FINAL